RXRX
RECURSION PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Biotechnology · US
$3.83
+8.19%Next report
Analyst consensus
- Next report date
- Nov 4, 2026
- EPS estimate
- -$0.24
- Revenue estimate
- $14.2M
Latest reported
- Last report date
- Aug 5, 2026
- EPS actual
- -$0.25
- EPS estimate
- -$0.24
- Revenue actual
- $7.3M
- Revenue estimate
- $11.0M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 5
- EPS misses (12Q)
- 6
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- +13.2%
- Revenue beats (12Q)
- 3
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 5, 2026 | -$0.24 | -$0.25 | Miss -4.17% | $7.3M |
| May 6, 2026 | -$0.30 | -$0.22 | Beat 26.67% | $6.3M |
| Feb 25, 2026 | -$0.28 | -$0.21 | Beat 25.00% | $35.5M |
| Nov 5, 2025 | -$0.38 | -$0.36 | Beat 5.26% | $5.2M |
| Feb 28, 2025 | -$0.44 | -$0.53 | Miss -20.45% | $4.5M |
| Aug 8, 2024 | -$0.35 | -$0.40 | Miss -14.29% | $14.4M |
| May 9, 2024 | -$0.43 | -$0.39 | Beat 9.30% | $13.8M |
| Feb 27, 2024 | -$0.46 | -$0.40 | Beat 13.04% | $10.9M |
| Nov 9, 2023 | -$0.38 | -$0.43 | Miss -13.16% | $10.1M |
| Feb 27, 2023 | -$0.15 | -$0.31 | Miss -106.67% | $13.7M |
| Mar 23, 2022 | -$0.30 | -$0.38 | Miss -26.67% | $2.5M |
| Nov 10, 2021 | -$0.28 | -$0.28 | In line | $2.5M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 4, 2026